To evaluate the association of 3 hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor (statin) use and concordant polypharmacy with disease-specific survival from endometrial cancer.
T he use of statins, 3 hydroxy-3-methyl-glutarylcoenzyme A reductase inhibitors, is widespread, because they are used in treating hyperlipidemia, a common condition. 1 These medications reversibly inhibit the conversion of 3 hydroxy-3-methyl-glutaryl-coenzyme A to mevalonate and reduce cholesterol. 2 Statin use has been associated with decreased incidence and death from cancers of the breast, colon, pancreas, gastrointestinal tract, liver, endometrium, and ovary. [3] [4] [5] [6] [7] Proposed mechanisms to explain the association of statin use with decreased cancer incidence and death include lowering of cholesterol and systemic antiinflammatory effects. 8, 9 Lower cholesterol may reduce metabolites that affect tumor apoptosis, inhibited angiogenesis, and impaired metastasis. Murine models of breast cancer when treated with statins were found to undergo increased apoptosis as well as decreased tumor cell proliferation. [10] [11] [12] Statins also reduced the proliferation of cancer cells in murine models of colon, liver, pancreatic, ovarian, and prostate cancers. [13] [14] [15] [16] Epidemiologic studies have shown an inverse association of statin use with the incidence of uterine and ovarian cancer. 17 Women in the Cancer in the Ovary and Uterus Study who used statins after diagnosis had an improved survival from ovarian cancer and a trend toward improved survival from endometrial cancer.
No prior study of statins and mortality and progression from endometrial cancer have distinguished between type 1 (endometrioid) and type 2 (nonendometrioid) tumors in the published literature in MEDLINE from 1946 until April 2015 (search terms: type 2 endometrial cancer, statins, nonendometrioid). The goal of our study was to assess the association of statin use with disease-specific survival from type 1 and type 2 endometrial cancer and the association of concordant polypharmacy to diseasespecific survival.
MATERIALS AND METHODS
Institutional review board approval was obtained to review all patients treated for endometrial cancer at Montefiore Medical Center from January 1, 1999, to December 31, 2009. Statin use, age, body mass index (calculated as weight (kg)/[height (m)] 2 ), race, diabetes, hyperlipidemia, hypertension, metformin, aspirin, and antihypertensive medications were obtained from anesthesia records on the day of surgical staging. Patients whose anesthesia records were unavailable were excluded from the analysis. Excluded records were assumed missing at random because all anesthesia records before the electronic medical record initiation were unobtainable. Histology, stage, grade, and date of death were obtained from review of all available records. Age was reported at the date of diagnosis. Histologic subtypes were divided into type 1 (endometrioid) and type 2 (nonendometrioid). Nonendometrioid subtypes included papillary serous, clear cell, mixed, and carcinosarcomas. Sarcomas and other histologies were excluded. Stage was determined by the 1988 International Federation of Gynecology and Obstetrics criteria. 18 Cause and date of death were obtained by review of records and the National Death Index. Survival was calculated from date of diagnosis to date of death from endometrial cancer. All data were entered by trained personnel and kept in datereferenced sequential files. Histopathologic and medication records were validated by physician-level data auditors. Periodic verification of randomly chosen data points with source documents was performed to ensure data fidelity during analysis.
Selected patient and tumor characteristics at the time of diagnosis were summarized as continuous, ordinal, or categorical variables. Dose potencies were calculated according to published data of mean percentage reduction in low dense lipoprotein levels 19 (see Appendix 1, available online at http://links.lww.com/AOG/A659).
Statin dose potency was categorized into three levels: less than 30% reduction in low-density lipoprotein (LDL), 30-50% reduction in LDL, and greater than 50% reduction in LDL.
Disease-specific survival was estimated using the Kaplan-Meier method and the stratified log rank test was used to compare survival between strata. Univariable and multivariable Cox proportional hazard regression models were fit to determine the variables associated with disease-specific mortality. Factors related to disease-specific mortality in patients with endometrial cancer found to have P,.10 in univariable analysis were included in the multivariable model. Variables with evidence of colinearity were excluded from the model. All analyses were performed using Stata 12.0. All P values are two-sided.
RESULTS
Of 985 patients with endometrial cancer, 983 were considered evaluable because verification of death from disease or living was available by hospital medical record or the National Death Index. Two patients who were not verifiable were excluded from the analysis. Of the remaining, 983,220 (22.4%) had documented statin use, 629 (64%) had documentation that they were not statin users, and 198 (20%) had incomplete charts (statin use could not be verified on the day of surgery). Five hundred ninety-one (57%) had type 1 and 338 (34%) had type 2 histology. Of the type 2 cancers, 87 (26%) patients were statin users. Compared with nonstatin users, those who used statin were older (68 compared with 63 years, P,.01) and more likely to have hypertension (89% compared with 59%, P,.01) and hyperlipidemia (99.5% compared with 13%, P,.01). They were more likely to use aspirin (39% compared with 13%, P,.01), metformin (24% compared with 9%), b-blockers (43% compared with 24%, P,.01) and were more often treated with radiation (46% compared with 35%, P,.01). Complete information on specific statin type (n5221) and dose (n5180) was available for 81% of patients (Table 1) . Unauthorized reproduction of this article is prohibited.
At the time of analysis, 280 patients (28%) had died of whom 230 (22%) patients had died of endometrial cancer, 48 (5%) patients had died without evidence of disease, and the cause of death for two patients was undetermined. In the subset of patients with confirmed statin use data (n5790), 18.6% (n541) of statin users had died of disease and 81.4% (n5180) were censored. In the statin nonusers, 25.8% (n5147) Fig. 5 ). Type 2 cancers were further studied using Cox models. In univariate models factors associated with disease-specific mortality included age, stage, radiation, aspirin, metformin, hyperlipidemia, and statin use ( Table 3) Unauthorized reproduction of this article is prohibited.
DISCUSSION
In this retrospective single-institution cohort, statin use was associated with an improved disease-specific survival for women with endometrial cancer. This association persisted for women with type 2 but not type 1 cancers after stratification for histologic subtype. There was also a synergistic relationship between stain and aspirin use. These data suggest that further study of statin and aspirin use in women with type 2 endometrial cancers should be considered.
Our data are in agreement with the published associations of decreased mortality from cancers for statin users compared with nonusers by a retrospective-based study by Neilsen et al. 20 In that populationbased study of Danish patients who had a diagnosis of cancer, the multivariable adjusted HR was 0.85 (95% CI 0.82-0.87) for statin users. Elmore et al 21 reported on improved overall survival for women with epithelial ovarian cancer who were statin users compared with nonusers (P5.04). Additionally, in a study of both endometrial and ovarian cancers, Lavie et al 17 found improved survival for ovarian (log rank P5.02, HR 0.45, 95% CI 0.23-0.87) and a trend toward improved survival for endometrial cancers for patients taking statin therapy.
The mechanism for the association of statin use with improved survival has not been fully explained. However, Schointuch et al 22 have reported antiproliferative and antimetastatic effects in vitro of endometrial cancer cell lines treated with statins as a result of modulation of the mitogen-activated protein kinase and AKT/mammalian target of rapamycin pathways. Effect of statin and aspirin use on development of deep vein thrombosis, as a contributor to mortality, has failed to show a decreased risk of thromboembolic events, so it is unlikely that the survival benefit is related to prevention of thrombosis. 23 Li et al 24 have reported that decreased LDL was associated with survival in advanced-stage epithelial ovarian cancers of predominately papillary serous histologic types. These data suggest biological plausibility for a mechanism related to lipid metabolism as an explanation of the effect of statin therapy on mortality from cancer.
There is an important distinction in our data from previous evaluations of the effect of statin on cancer mortality in that none of the previous studies evaluated the effect of histologic type of cancer. 17, 20 Differences in the effect of statins on histologic type may reflect biomolecular pathways that are influenced by statin and aspirin use. Additionally, in the work by Lavie et al, the survival advantage was only appreciated when patients used statins after diagnosis in their cohort. By the exclusion of patients using statin before diagnosis, those data may have been subject to time lag bias. The cohort of Lavie et al also included both ovarian and uterine cancers and did not attempt distinction of histologic subtypes or polypharmacy. Similarly, in a meta-analysis of the effect of statin use on risk of gynecologic cancers, there was no association of decreased incidence of endometrial cancers found for statin users. 25 However, in this meta-analysis, there was no distinction made between histopathologic subtypes of endometrial cancers. Studies confined to Unauthorized reproduction of this article is prohibited.
